Inhibition of the enzyme activity of cytochrome P450 1A1, 1A2 and 3A4 by fucoxanthin, a marine carotenoid

Oncology Letters

Volumn 6, Issue 3, 2013, Pages 860-864

  Satomi, Yoshiko ^a   Nishino, Hoyoku ^b,c  

^a SUZUKA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c RITSUMEIKAN UNIVERSITY   (Japan)

Author keywords

Cancer prevention; Carotenoid; Cytochrome P450; Fucoxanthin

Indexed keywords

CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 3A4; ETHOXYRESORUFIN DEETHYLASE; FUCOXANTHIN;

ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; NORTHERN BLOTTING;

EID: 84880404504     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1457     Document Type: Article

References (25)

1. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh J P, Meyskens FL Jr, Valanis B, Williams JH Jr, Barnhart S, Cherniack MG, Brodkin CA and Hammar S: Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst 88: 1550-1559, 1996.
2. Paolini M, Cantelli-Forti G, Perocco P, Pedulli GF, Abdel-Rahman SZ and Legator MS: Co-carcinogenic effect of beta-carotene. Nature 398: 760-761, 1999.
3. Guengerich FP: Cytochrome P450: what have we learned and what are the future issues? Drug Metab Rev 36: 159-197, 2004.
4. Nebert DW, Wikvall K and Miller WL: Human cytochromes P450 in health and disease. Philos Trans R Soc Lond B Biol Sci 368: 20120431, 2013.
5. Zhang JY, Wang Y and Prakash C: Xenobiotic-metabolizing enzymes in human lung. Curr Drug Metab 7: 939-948, 2006.
6. Shimada T: Xenobiotic-metabolizing enzymes involved in activation and detoxification of carcinogenic polycyclic aromatic hydrocarbons. Drug Metab Pharmacokinet 21: 257-276, 2006.
7. Shimada T and Fujii-Kuriyama Y: Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and 1B1. Cancer Sci 95: 1-6, 2004.
8. Ma Q and Lu AY: CYP1A induction and human risk assessment: an evolving tale of in vitro and in vivo studies. Drug Metab Dispos 35: 1009-1016, 2007.
9. Kamdem LK, Meineke I, Gödtel-Armbrust U, Brokmöller J and Wojnowski L: Dominant contribution of P450 3A4 to the hepatic carcinogenic activation of aflatoxin B1. Chem Res of Toxicol 19: 577-586, 2006.
10. Zhou SF, Xue CC, Yu XQ and Wang G: Metabolic activation of herbal and dietary constituents and its clinical and toxicological implications: an update. Curr Drug Metab 8: 526-553 2007.
11. Ohno M, Darwish WS, Ikenaka Y, Miki W and Ishizuka M: Astaxanthin can alter CYP1A-dependent activities via two different mechanisms: induction of protein expression and inhibition of NADPH P450 reductase dependent electron transfer. Food Chem Toxicol 49: 285-1291, 2011.
12. Gradelet S, Astorg P, Pineau T, Canivenc MC, Siess MH, Leclerc J and Lesca P: Ah receptor-dependent CYP1A induction by two carotenoids, canthaxanthin and b-apo-8'-carotenal, with no affinity for the TCDD binding site. Biochem Pharmacol 54: 307-315, 1997.
13. Breinholt V, Lauridsen ST, Daneshvar B and Jakobsen J: Dose-response effects of lycopene on selected drug-metabolizing and antioxidant enzymes in the rat. Cancer Lett 154: 201-210, 2000.
14. Astorg P, Gradelet S, Leclerc J and Siess MH: Effects of provitamin A or non-provitamin A carotenoids on liver xenobiotic-metabolizing enzymes in mice. Nutr Cancer 27: 245-249, 1997.
15. Liu CL, Lim YP and Hu ML: Fucoxanthin attenuates rifampin-induced cytochrome P450 3A4 (CYP3A4) and multiple drug resistance 1 (MDR1) gene expression through pregnane X receptor (PXR)-mediated pathways in human hepatoma HepG2 and colon adenocarcinoma LS174T cells. Mar Drugs 10: 242-257, 2012.
16. Firdous AP, Sindhu ER, Ramnath V and Kuttan R: Anti-mutagenic and anti-carcinogenic potential of the carotenoid meso-zeaxanthin. Asian Pac J Cancer Prev 11: 1795-1800, 2010.
17. Wang H and Leung LK: The carotenoid lycopene differentially regulates phase I and II enzymes in dimethylbenz[a]anthracene-induced MCF-7 cells. Nutrition 26: 1181-1187, 2010.
18. Gradelet S, Astorg P, Le Bon AM, Bergès R and Suschetet M: Modulation of aflatoxin B1 carcinogenicity, genotoxicity and metabolism in rat liver by dietary carotenoids: evidence for a protective effect of CYP1A inducers. Cancer Lett 114: 221-223, 1997.
19. Kim KN, Ahn G, Heo SJ, Kang SM, Kang MC, Yang HM, Kim D, Roh SW, Kim SK, Jeon BT, Park PJ, Jung WK and Jeon YJ: Inhibition of tumor growth in vitro and in vivo by fucoxanthin against melanoma B16F10 cells. Environ Toxicol Pharmacol 35: 39-46, 2013.
20. Yu RX, Hu XM, Xu SQ, Jiang ZJ and Yang W: Effects of fucoxanthin on proliferation and apoptosis in human gastric adenocarcinoma MGC-803 cells via JAK/STAT signal pathway. Eur J Pharmacol 657: 10-19, 2011.
21. Wang J, Chen S, Xu S, Yu X, Ma D, Hu X and Cao X: In vivo induction of apoptosis by fucoxanthin, a marine carotenoid, associated with down-regulating STAT3/EGFR signaling in sarcoma 180 (S180) xenografts-bearing mice. Mar Drug 10: 2055-2068, 2012.
22. Kim JM, Araki S, Kim DJ, Park CB, Takasuka N, Baba-Toriyama H, Ota T, Nir Z, F Khachik, Shimidzu N, Tanaka Y, Osawa T, Uraji T, Murakoshi M, Nishino H and Tsuda H: Chemopreventive effects of carotenoids and curcumins on mouse colon carcinogenesis after 1,2-dimethyhydrazine initiation. Carcinogenesis 19: 81-85, 1998.
23. Okuzumi J, Takahashi T, Yamane T, Kitao Y, Inagake M, Ohya K, Nishino H and Tanaka Y: Inhibitory effects of fucoxanthin, a natural carotenoid, on N-ethyl-N'-nitro-N-nitrosoguanidine-induced mouse duodenal carcinogenesis. Cancer Lett 68: 159-168, 1993.
24. Ciolino HP, MacDonald CJ and Yeh GC: Inhibition of carcinogen-activating enzymes by 16alpha-fluoro-5-androsten-17-one. Cancer Res 62: 3685-3690, 2002.
25. Goralczyk R: Beta-carotene and lung cancer in smokers: review of hypotheses and status of research. Nutr Cancer 61: 767-774, 2009.